DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Extavia (Interferon Beta-1B) - Published Studies


Extavia Related Published Studies

Well-designed clinical trials related to Extavia (Interferon Beta-1B)

Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. [2014]

Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. [2014]

Interferon beta for secondary progressive multiple sclerosis. [2012]

Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. [2011.08.30]

Interferon beta-1b and glatiramer acetate effects on permanent black hole evolution. [2011.04.05]

[Interferon beta for multiple sclerosis. How much is good enough?]. [2010.12]

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. [2010.06.08]

Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial. [2010.04]

SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology. [2009.12.14]

Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study. [2009.12]

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. [2009.12]

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. [2009.11]

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. [2009.10]

250 mug or 500 mug interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. [2009.10]

Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. [2009.08]

The OPTimization of Interferon for MS Study: 375 mug interferon beta-1b in suboptimal responders. [2008.09]

Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers. [2008.08.13]

Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. [2008.08]

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: A multicenter, randomized, double-blind, parallel-group pilot study. [2008.06]

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. [2008.04]

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. [2007.09]

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. [2007.08.04]

Well-designed clinical trials possibly related to Extavia (Interferon Beta-1B)

Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis. [2011.04]

Long-term follow-up of clinical trials of multiple sclerosis therapies. [2011.01.04]

The therapeutic effect of Avonex, Rebif and Betaferon on EDSS and relapse in multiple sclerosis: a comparative study. [2010.03]

A reassessment of the plateauing relationship between T2 lesion load and disability in MS. [2009.11.10]

Serum levels of CXCL13 are elevated in active multiple sclerosis. [2009.11]

Adverse drug reactions after 24-month treatment with two-dosage regimens of betaferon in patients with multiple sclerosis. [2009.07]

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. [2009.06.09]

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. [2009.05.20]

Subtraction MR images in a multiple sclerosis multicenter clinical trial setting. [2009.02]

Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. [2008.08]

Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis. [2008.08]

A clinical study of multiple sclerosis patients treated with betaferon. [2008.07]

Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis. [2008.05]

Adherence to therapy: using an evidence-based protocol. [2007.11]

Lack of association between antimyelin antibodies and progression to multiple sclerosis. [2007.01.25]

Other research related to Extavia (Interferon Beta-1B)

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. [2014]

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. [2011.12]

Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis: Five-Year Clinical Trial Follow-up. [2011.11]

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. [2011.09.30]

Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials. [2011.05.26]

Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy. [2011.04]

Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. [2011.03.15]

Interferon-beta-1b: a review of its use in multiple sclerosis. [2011.01.01]

Drug-induced systemic lupus erythematosus in interferon beta-1b therapy. [2011]

Therapeutic efficacy of interferon beta-1b in Japanese patients with optic-spinal multiple sclerosis. [2011]

Apolipoprotein alleles and the response to interferon-beta-1b in multiple sclerosis. [2011]

A meta-analysis of the efficacy and tolerability of interferon-beta in multiple sclerosis, overall and by drug and disease type. [2010.10]

Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon beta. [2010.10]

Persistent interferon-ss-1b-induced psychosis in a patient with multiple sclerosis. [2010.10]

Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. [2010.09]

Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group. [2010.05]

Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. [2010.01]

Neutralizing antibodies to 500 microg interferon beta-1b: 28-month results of the IDEAS extension trial. [2010.01]

Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. [2010]

The effect of interferon beta 1B on bone mineral density in multiple sclerosis patients. [2010]

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. [2010]

Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy? [2010]

Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial. [2010]

Cutaneous vasculitis associated with interferon beta-1b treatment for multiple sclerosis. [2009.09]

Effects of relapsing-remitting multiple sclerosis treatment with interferon beta-1b results of a three-year follow-up study. [2009.06]

Other possibly related research studies

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. [2010.08]

Increasing use of disease modifying drugs for MS in Canada. [2010.05]

A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective. [2010.04]

Betaferon in the treatment of multiple sclerosis. [2009.09]

Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study. [2010.04.14]

Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. [2010.02]

Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. [2010.03]

[Treatment of NMO] [2009.11]

Magnetic resonance evidence of cerebellar cortical pathology in multiple sclerosis. [2010.04]

Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. [2009.11]

Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. [2010.03]

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. [2009.09]

Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. [2009.10]

[Therapy of multiple sclerosis] [2009.03]

Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS. [2011]

Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. [2011.12]

Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis. [2011.06]

Clinical consequences of MRI activity in treated multiple sclerosis. [2011.09]

The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment. [2011.07]

Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. [2011.05]

Current disease-modifying treatment of multiple sclerosis. [2011.03]

Management of optic neuritis. [2011.03]

Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland. [2011.06]

Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation. [2011.01]

[Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results]. [2010.09]

Medication adherence with disease modifying treatments for multiple sclerosis among US employees. [2010]

A new treatment era in multiple sclerosis: clinical applications of new concepts. [2011.07.15]

Cytokine patterns after therapy with Avonex(R), Rebif(R), Betaferon(R) and CinnoVex in relapsing-remitting multiple sclerosis in Iranian patients. [2010.10]

The current landscape and unmet needs in multiple sclerosis. [2010.09]

Relapsing demyelinating CNS disease in a Korean pediatric population: multiple sclerosis versus neuromyelitis optica. [2011.01]

Impact of inflammation on brain volume in multiple sclerosis. [2012]

Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis. [2011]

The therapeutic effect of Avonex, Rebif and Betaferon on EDSS and relapse in multiple sclerosis: a comparative study. [2010]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017